View ValuationMonstarlab 将来の成長Future 基準チェック /06現在、 Monstarlabの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率IT 収益成長10.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • Apr 05Full year 2025 earnings released: JP¥5.95 loss per share (vs JP¥285 loss in FY 2024)Full year 2025 results: JP¥5.95 loss per share (improved from JP¥285 loss in FY 2024). Revenue: JP¥7.80b (down 22% from FY 2024). Net loss: JP¥337.0m (loss narrowed 97% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings.Reported Earnings • Feb 28Full year 2025 earnings released: JP¥5.95 loss per share (vs JP¥285 loss in FY 2024)Full year 2025 results: JP¥5.95 loss per share (improved from JP¥285 loss in FY 2024). Revenue: JP¥7.80b (down 22% from FY 2024). Net loss: JP¥337.0m (loss narrowed 97% from FY 2024).お知らせ • Feb 27Monstarlab Inc., Annual General Meeting, Mar 31, 2026Monstarlab Inc., Annual General Meeting, Mar 31, 2026.分析記事 • Feb 16We Think Monstarlab (TSE:5255) Is Taking Some Risk With Its DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Jan 09Why We Like The Returns At Monstarlab (TSE:5255)What are the early trends we should look for to identify a stock that could multiply in value over the long term...お知らせ • Dec 27Monstarlab Inc. to Report Fiscal Year 2025 Results on Feb 13, 2026Monstarlab Inc. announced that they will report fiscal year 2025 results on Feb 13, 2026分析記事 • Nov 28There's Reason For Concern Over Monstarlab Inc.'s (TSE:5255) Massive 31% Price JumpThose holding Monstarlab Inc. ( TSE:5255 ) shares would be relieved that the share price has rebounded 31% in the last...Reported Earnings • Nov 18Third quarter 2025 earnings released: EPS: JP¥8.53 (vs JP¥53.64 loss in 3Q 2024)Third quarter 2025 results: EPS: JP¥8.53 (up from JP¥53.64 loss in 3Q 2024). Revenue: JP¥2.05b (down 7.6% from 3Q 2024). Net income: JP¥553.0m (up JP¥2.39b from 3Q 2024). Profit margin: 27% (up from net loss in 3Q 2024).分析記事 • Oct 29Is Monstarlab (TSE:5255) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Reported Earnings • Aug 16Second quarter 2025 earnings released: JP¥2.18 loss per share (vs JP¥162 loss in 2Q 2024)Second quarter 2025 results: JP¥2.18 loss per share (improved from JP¥162 loss in 2Q 2024). Revenue: JP¥1.88b (down 26% from 2Q 2024). Net loss: JP¥115.2m (loss narrowed 98% from 2Q 2024).お知らせ • Jul 02Monstarlab Inc. announced that it has received ¥70.000184 million in fundingOn June 30, 2024. Monstarlab Inc. announced that it has closed the Transaction.お知らせ • Jun 13Monstarlab Inc. announced that it expects to receive ¥70.000184 million in fundingMonstarlab Inc. announced a private placement of 573,772 shares at a price of ¥122 per share for gross proceeds of ¥ 70,000,184 through third party allotment on June 13, 2025.The transaction includes participation from Hiroki Inagawa for 282,787 shares, Eiichi Matsushima for 245,902 shares, Tomoyuki Uno for 28,689 shares, Tatsuro Usui for 16,394 shares. The transaction is approved by board of the directors of the company. The transaction is expected to close on June 30, 2025.Reported Earnings • May 21First quarter 2025 earnings released: JP¥3.09 loss per share (vs JP¥9.91 loss in 1Q 2024)First quarter 2025 results: JP¥3.09 loss per share (improved from JP¥9.91 loss in 1Q 2024). Revenue: JP¥1.90b (down 40% from 1Q 2024). Net loss: JP¥137.0m (loss narrowed 60% from 1Q 2024).Board Change • May 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Auditor Yuko Miura was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 16+ 1 more updateMonstarlab Inc. to Report Q1, 2025 Results on May 15, 2025Monstarlab Inc. announced that they will report Q1, 2025 results on May 15, 2025Reported Earnings • Apr 05Full year 2024 earnings released: JP¥285 loss per share (vs JP¥70.06 loss in FY 2023)Full year 2024 results: JP¥285 loss per share (further deteriorated from JP¥70.06 loss in FY 2023). Revenue: JP¥10.0b (down 25% from FY 2023). Net loss: JP¥9.95b (loss widened 322% from FY 2023).New Risk • Mar 24New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 34% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.3% average weekly change). Negative equity (-JP¥4.8b). Earnings have declined by 49% per year over the past 5 years. Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Minor Risk Market cap is less than US$100m (JP¥3.76b market cap, or US$25.1m).New Risk • Feb 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-JP¥4.8b). Earnings have declined by 49% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (JP¥3.94b market cap, or US$26.4m).New Risk • Feb 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.0% average weekly change). Negative equity (-JP¥4.8b). Earnings have declined by 49% per year over the past 5 years. Minor Risk Market cap is less than US$100m (JP¥3.29b market cap, or US$21.7m).お知らせ • Feb 17Monstar Lab, Inc., Annual General Meeting, Mar 28, 2025Monstar Lab, Inc., Annual General Meeting, Mar 28, 2025.Reported Earnings • Feb 16Full year 2024 earnings released: JP¥285 loss per share (vs JP¥70.06 loss in FY 2023)Full year 2024 results: JP¥285 loss per share (further deteriorated from JP¥70.06 loss in FY 2023). Revenue: JP¥10.0b (down 25% from FY 2023). Net loss: JP¥9.95b (loss widened 322% from FY 2023).お知らせ • Jan 17+ 1 more updateMonstar Lab, Inc. to Report Q3, 2025 Results on Nov 14, 2025Monstar Lab, Inc. announced that they will report Q3, 2025 results on Nov 14, 2025New Risk • Jan 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-JP¥3.0b). Earnings have declined by 46% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Shareholders have been diluted in the past year (9.4% increase in shares outstanding). Market cap is less than US$100m (JP¥3.30b market cap, or US$21.0m).分析記事 • Dec 05Monstar Lab, Inc. (TSE:5255) Could Be Riskier Than It LooksMonstar Lab, Inc.'s ( TSE:5255 ) price-to-sales (or "P/S") ratio of 0.3x may look like a pretty appealing investment...お知らせ • Sep 20Calvin Rodney Sylvinus Hart agreed to acquire Genieology from Monstar Lab, Inc. (TSE:5255) for approximately ¥240 million.Calvin Rodney Sylvinus Hart agreed to acquire Genieology from Monstar Lab, Inc. (TSE:5255) for approximately ¥240 million on September 19, 2024. A cash consideration of ¥241 million will be paid by the buyer. As part of consideration, ¥241 million is paid towards common equity of Genieology. As of December 31, 2023, Genieology reported total assets of ¥459 million and total common equity of ¥275 million. The expected completion of the transaction is September 30, 2024.Reported Earnings • Aug 19Second quarter 2024 earnings released: JP¥162 loss per share (vs JP¥32.03 loss in 2Q 2023)Second quarter 2024 results: JP¥162 loss per share (further deteriorated from JP¥32.03 loss in 2Q 2023). Revenue: JP¥2.54b (down 24% from 2Q 2023). Net loss: JP¥5.55b (loss widened 406% from 2Q 2023).Reported Earnings • May 18First quarter 2024 earnings released: JP¥9.91 loss per share (vs JP¥6.20 profit in 1Q 2023)First quarter 2024 results: JP¥9.91 loss per share (down from JP¥6.20 profit in 1Q 2023). Revenue: JP¥3.18b (down 13% from 1Q 2023). Net loss: JP¥340.0m (down 273% from profit in 1Q 2023).分析記事 • Apr 11A Piece Of The Puzzle Missing From Monstar Lab, Inc.'s (TSE:5255) 32% Share Price ClimbMonstar Lab, Inc. ( TSE:5255 ) shares have had a really impressive month, gaining 32% after a shaky period beforehand...分析記事 • Feb 26Slammed 34% Monstar Lab, Inc. (TSE:5255) Screens Well Here But There Might Be A CatchMonstar Lab, Inc. ( TSE:5255 ) shares have had a horrible month, losing 34% after a relatively good period beforehand...お知らせ • Feb 16Monstar Lab, Inc., Annual General Meeting, Mar 28, 2024Monstar Lab, Inc., Annual General Meeting, Mar 28, 2024.お知らせ • Dec 06Monstar Lab, Inc. to Report Fiscal Year 2023 Results on Feb 14, 2024Monstar Lab, Inc. announced that they will report fiscal year 2023 results on Feb 14, 2024お知らせ • Dec 05+ 2 more updatesMonstar Lab, Inc. to Report Q2, 2024 Results on Aug 14, 2024Monstar Lab, Inc. announced that they will report Q2, 2024 results on Aug 14, 2024お知らせ • Sep 22Monstar Lab, Inc. (TSE:5255) agreed to acquire ExecutiveSearch.AI K.K.Monstar Lab, Inc. (TSE:5255) agreed to acquire ExecutiveSearch.AI K.K. on September 20, 2023. The consideration for 86 shares to be acquired in October 2023 is ¥413 million. The agreement states that the acquisition is completed in stages: 14 shares will be acquired in 2024, 14 shares in 2025, 14 shares in 2026, and 15 shares in 2027. The acquisition in 2027 completes the transaction, and all the issued shares of common stock will have been acquired. ExecutiveSearch.AI reported net assets of ¥69 million, total assets of ¥103 million, net sales of ¥190 million and operating profit of ¥11 million as at September 30, 2022. The advisory fees for this transaction is ¥12 million. The transaction is expected to close in 2027.New Risk • Aug 17New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥14.4b (US$98.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (JP¥14.4b market cap, or US$98.4m).Board Change • Mar 28Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent External Director Chiamin Lai was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Monstarlab は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TSE:5255 - アナリストの将来予測と過去の財務データ ( )JPY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20257,795-424-201-147N/A9/30/20257,891-1,911-123-52N/A6/30/20258,060-4,306-775-692N/A3/31/20258,724-9,744-2,822-2,708N/A12/31/202410,003-9,947-3,264-3,086N/A9/30/202411,179-9,000-4,091-3,867N/A6/30/202412,307-8,256-4,552-4,110N/A3/31/202412,887-2,892-3,824-3,340N/A12/31/202313,346-2,355-3,979-3,518N/A9/30/202314,255-1,456N/AN/AN/A6/30/202314,605-222N/AN/AN/A3/31/202314,800-609N/AN/AN/A12/31/202214,270-674N/AN/AN/A12/31/20219,346-3,053N/AN/AN/A12/31/20207,419-1,274N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 5255の予測収益成長が 貯蓄率 ( 0.8% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 5255の収益がJP市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 5255の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 5255の収益がJP市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 5255の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 5255の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YSoftware 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/08 16:53終値2026/05/08 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Monstarlab Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Shingo KumazawaDaiwa Securities Co. Ltd.
Reported Earnings • Apr 05Full year 2025 earnings released: JP¥5.95 loss per share (vs JP¥285 loss in FY 2024)Full year 2025 results: JP¥5.95 loss per share (improved from JP¥285 loss in FY 2024). Revenue: JP¥7.80b (down 22% from FY 2024). Net loss: JP¥337.0m (loss narrowed 97% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Feb 28Full year 2025 earnings released: JP¥5.95 loss per share (vs JP¥285 loss in FY 2024)Full year 2025 results: JP¥5.95 loss per share (improved from JP¥285 loss in FY 2024). Revenue: JP¥7.80b (down 22% from FY 2024). Net loss: JP¥337.0m (loss narrowed 97% from FY 2024).
お知らせ • Feb 27Monstarlab Inc., Annual General Meeting, Mar 31, 2026Monstarlab Inc., Annual General Meeting, Mar 31, 2026.
分析記事 • Feb 16We Think Monstarlab (TSE:5255) Is Taking Some Risk With Its DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • Jan 09Why We Like The Returns At Monstarlab (TSE:5255)What are the early trends we should look for to identify a stock that could multiply in value over the long term...
お知らせ • Dec 27Monstarlab Inc. to Report Fiscal Year 2025 Results on Feb 13, 2026Monstarlab Inc. announced that they will report fiscal year 2025 results on Feb 13, 2026
分析記事 • Nov 28There's Reason For Concern Over Monstarlab Inc.'s (TSE:5255) Massive 31% Price JumpThose holding Monstarlab Inc. ( TSE:5255 ) shares would be relieved that the share price has rebounded 31% in the last...
Reported Earnings • Nov 18Third quarter 2025 earnings released: EPS: JP¥8.53 (vs JP¥53.64 loss in 3Q 2024)Third quarter 2025 results: EPS: JP¥8.53 (up from JP¥53.64 loss in 3Q 2024). Revenue: JP¥2.05b (down 7.6% from 3Q 2024). Net income: JP¥553.0m (up JP¥2.39b from 3Q 2024). Profit margin: 27% (up from net loss in 3Q 2024).
分析記事 • Oct 29Is Monstarlab (TSE:5255) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Reported Earnings • Aug 16Second quarter 2025 earnings released: JP¥2.18 loss per share (vs JP¥162 loss in 2Q 2024)Second quarter 2025 results: JP¥2.18 loss per share (improved from JP¥162 loss in 2Q 2024). Revenue: JP¥1.88b (down 26% from 2Q 2024). Net loss: JP¥115.2m (loss narrowed 98% from 2Q 2024).
お知らせ • Jul 02Monstarlab Inc. announced that it has received ¥70.000184 million in fundingOn June 30, 2024. Monstarlab Inc. announced that it has closed the Transaction.
お知らせ • Jun 13Monstarlab Inc. announced that it expects to receive ¥70.000184 million in fundingMonstarlab Inc. announced a private placement of 573,772 shares at a price of ¥122 per share for gross proceeds of ¥ 70,000,184 through third party allotment on June 13, 2025.The transaction includes participation from Hiroki Inagawa for 282,787 shares, Eiichi Matsushima for 245,902 shares, Tomoyuki Uno for 28,689 shares, Tatsuro Usui for 16,394 shares. The transaction is approved by board of the directors of the company. The transaction is expected to close on June 30, 2025.
Reported Earnings • May 21First quarter 2025 earnings released: JP¥3.09 loss per share (vs JP¥9.91 loss in 1Q 2024)First quarter 2025 results: JP¥3.09 loss per share (improved from JP¥9.91 loss in 1Q 2024). Revenue: JP¥1.90b (down 40% from 1Q 2024). Net loss: JP¥137.0m (loss narrowed 60% from 1Q 2024).
Board Change • May 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Auditor Yuko Miura was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 16+ 1 more updateMonstarlab Inc. to Report Q1, 2025 Results on May 15, 2025Monstarlab Inc. announced that they will report Q1, 2025 results on May 15, 2025
Reported Earnings • Apr 05Full year 2024 earnings released: JP¥285 loss per share (vs JP¥70.06 loss in FY 2023)Full year 2024 results: JP¥285 loss per share (further deteriorated from JP¥70.06 loss in FY 2023). Revenue: JP¥10.0b (down 25% from FY 2023). Net loss: JP¥9.95b (loss widened 322% from FY 2023).
New Risk • Mar 24New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 34% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.3% average weekly change). Negative equity (-JP¥4.8b). Earnings have declined by 49% per year over the past 5 years. Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Minor Risk Market cap is less than US$100m (JP¥3.76b market cap, or US$25.1m).
New Risk • Feb 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-JP¥4.8b). Earnings have declined by 49% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (JP¥3.94b market cap, or US$26.4m).
New Risk • Feb 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.0% average weekly change). Negative equity (-JP¥4.8b). Earnings have declined by 49% per year over the past 5 years. Minor Risk Market cap is less than US$100m (JP¥3.29b market cap, or US$21.7m).
お知らせ • Feb 17Monstar Lab, Inc., Annual General Meeting, Mar 28, 2025Monstar Lab, Inc., Annual General Meeting, Mar 28, 2025.
Reported Earnings • Feb 16Full year 2024 earnings released: JP¥285 loss per share (vs JP¥70.06 loss in FY 2023)Full year 2024 results: JP¥285 loss per share (further deteriorated from JP¥70.06 loss in FY 2023). Revenue: JP¥10.0b (down 25% from FY 2023). Net loss: JP¥9.95b (loss widened 322% from FY 2023).
お知らせ • Jan 17+ 1 more updateMonstar Lab, Inc. to Report Q3, 2025 Results on Nov 14, 2025Monstar Lab, Inc. announced that they will report Q3, 2025 results on Nov 14, 2025
New Risk • Jan 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-JP¥3.0b). Earnings have declined by 46% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Shareholders have been diluted in the past year (9.4% increase in shares outstanding). Market cap is less than US$100m (JP¥3.30b market cap, or US$21.0m).
分析記事 • Dec 05Monstar Lab, Inc. (TSE:5255) Could Be Riskier Than It LooksMonstar Lab, Inc.'s ( TSE:5255 ) price-to-sales (or "P/S") ratio of 0.3x may look like a pretty appealing investment...
お知らせ • Sep 20Calvin Rodney Sylvinus Hart agreed to acquire Genieology from Monstar Lab, Inc. (TSE:5255) for approximately ¥240 million.Calvin Rodney Sylvinus Hart agreed to acquire Genieology from Monstar Lab, Inc. (TSE:5255) for approximately ¥240 million on September 19, 2024. A cash consideration of ¥241 million will be paid by the buyer. As part of consideration, ¥241 million is paid towards common equity of Genieology. As of December 31, 2023, Genieology reported total assets of ¥459 million and total common equity of ¥275 million. The expected completion of the transaction is September 30, 2024.
Reported Earnings • Aug 19Second quarter 2024 earnings released: JP¥162 loss per share (vs JP¥32.03 loss in 2Q 2023)Second quarter 2024 results: JP¥162 loss per share (further deteriorated from JP¥32.03 loss in 2Q 2023). Revenue: JP¥2.54b (down 24% from 2Q 2023). Net loss: JP¥5.55b (loss widened 406% from 2Q 2023).
Reported Earnings • May 18First quarter 2024 earnings released: JP¥9.91 loss per share (vs JP¥6.20 profit in 1Q 2023)First quarter 2024 results: JP¥9.91 loss per share (down from JP¥6.20 profit in 1Q 2023). Revenue: JP¥3.18b (down 13% from 1Q 2023). Net loss: JP¥340.0m (down 273% from profit in 1Q 2023).
分析記事 • Apr 11A Piece Of The Puzzle Missing From Monstar Lab, Inc.'s (TSE:5255) 32% Share Price ClimbMonstar Lab, Inc. ( TSE:5255 ) shares have had a really impressive month, gaining 32% after a shaky period beforehand...
分析記事 • Feb 26Slammed 34% Monstar Lab, Inc. (TSE:5255) Screens Well Here But There Might Be A CatchMonstar Lab, Inc. ( TSE:5255 ) shares have had a horrible month, losing 34% after a relatively good period beforehand...
お知らせ • Feb 16Monstar Lab, Inc., Annual General Meeting, Mar 28, 2024Monstar Lab, Inc., Annual General Meeting, Mar 28, 2024.
お知らせ • Dec 06Monstar Lab, Inc. to Report Fiscal Year 2023 Results on Feb 14, 2024Monstar Lab, Inc. announced that they will report fiscal year 2023 results on Feb 14, 2024
お知らせ • Dec 05+ 2 more updatesMonstar Lab, Inc. to Report Q2, 2024 Results on Aug 14, 2024Monstar Lab, Inc. announced that they will report Q2, 2024 results on Aug 14, 2024
お知らせ • Sep 22Monstar Lab, Inc. (TSE:5255) agreed to acquire ExecutiveSearch.AI K.K.Monstar Lab, Inc. (TSE:5255) agreed to acquire ExecutiveSearch.AI K.K. on September 20, 2023. The consideration for 86 shares to be acquired in October 2023 is ¥413 million. The agreement states that the acquisition is completed in stages: 14 shares will be acquired in 2024, 14 shares in 2025, 14 shares in 2026, and 15 shares in 2027. The acquisition in 2027 completes the transaction, and all the issued shares of common stock will have been acquired. ExecutiveSearch.AI reported net assets of ¥69 million, total assets of ¥103 million, net sales of ¥190 million and operating profit of ¥11 million as at September 30, 2022. The advisory fees for this transaction is ¥12 million. The transaction is expected to close in 2027.
New Risk • Aug 17New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥14.4b (US$98.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (JP¥14.4b market cap, or US$98.4m).
Board Change • Mar 28Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent External Director Chiamin Lai was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.